Charles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Charles Schwab Investment Management Inc. lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 753,363 shares of the specialty pharmaceutical company’s stock after buying an additional 40,968 shares during the period. Charles Schwab Investment Management Inc. owned about 1.36% of Supernus Pharmaceuticals worth $27,242,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. raised its holdings in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 1.1% during the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after purchasing an additional 7,833 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Supernus Pharmaceuticals by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock valued at $14,449,000 after buying an additional 27,134 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 4.0% during the fourth quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company’s stock valued at $10,730,000 after buying an additional 11,321 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 2.9 %

SUPN opened at $32.16 on Tuesday. The firm’s 50 day simple moving average is $36.13 and its two-hundred day simple moving average is $35.15. The company has a market capitalization of $1.79 billion, a PE ratio of 30.06 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,104 shares of company stock worth $440,263. Corporate insiders own 9.30% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on SUPN shares. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.